AG2R LA Mondiale Gestion D Actifs Makes New Investment in Natera, Inc. $NTRA

AG2R LA Mondiale Gestion D Actifs acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,033 shares of the medical research company’s stock, valued at approximately $1,136,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. HighPoint Advisor Group LLC increased its holdings in Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company’s stock worth $308,000 after purchasing an additional 468 shares in the last quarter. Amalgamated Bank grew its holdings in shares of Natera by 9.8% in the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock valued at $1,173,000 after acquiring an additional 740 shares in the last quarter. Comerica Bank grew its holdings in shares of Natera by 24.1% in the first quarter. Comerica Bank now owns 141,106 shares of the medical research company’s stock valued at $19,954,000 after acquiring an additional 27,379 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Natera by 32.3% in the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock valued at $120,000 after acquiring an additional 207 shares in the last quarter. Finally, Teza Capital Management LLC bought a new position in shares of Natera in the fourth quarter valued at approximately $221,000. 99.90% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 5,079 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $166.53, for a total value of $845,805.87. Following the sale, the chief executive officer owned 158,514 shares in the company, valued at approximately $26,397,336.42. This trade represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider John Fesko sold 678 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $155.46, for a total value of $105,401.88. Following the completion of the sale, the insider owned 152,747 shares in the company, valued at $23,746,048.62. This trade represents a 0.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,423 shares of company stock valued at $8,459,656 in the last ninety days. 5.63% of the stock is owned by insiders.

Natera Price Performance

NASDAQ:NTRA opened at $168.51 on Friday. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $183.00. The company has a market cap of $23.13 billion, a P/E ratio of -88.23 and a beta of 1.68. The stock’s fifty day moving average price is $155.18 and its two-hundred day moving average price is $154.13.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. During the same quarter last year, the business posted ($0.30) EPS. The company’s quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NTRA. Royal Bank Of Canada set a $268.00 target price on Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Wall Street Zen downgraded Natera from a “hold” rating to a “sell” rating in a research note on Saturday, May 17th. Morgan Stanley reiterated an “overweight” rating and set a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Stephens reiterated an “overweight” rating and set a $183.00 price target on shares of Natera in a research note on Friday, August 15th. Finally, Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 price target for the company in a research note on Monday, July 28th. One research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company’s stock. According to MarketBeat, Natera has an average rating of “Buy” and an average price target of $194.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.